( May 9, 2025, 1:46 PM EDT) -- WASHINGTON, D.C. — In a pair of opinions, two Federal Circuit U.S. Court of Appeals panels ruled against Incyte Corp. and a related entity in patent disputes that involved Sun Pharmaceutical Industries Inc. and the compound ruxolitinib, the appellate court reversed a New Jersey federal judge’s grant of preliminary injunction in Incyte’s favor and said the company lacked standing to challenge a finding from U.S. Patent Trial and Appeal Board (PTAB) that it failed to show the invalidity of Sun’s patent....